However, we believe that the associations found between PD-L1 expression, TMB, and genetic alterations, as well as genetic alterations associated with response rate and specific genomic profiles in fast disease progression, provide reasonable evidence to justify further research with a larger sample size, continuing the search for reliable prognostic biomarkers to facilitate the selection of NSCLC treatment solutions. This evidence concerns the gene CD274 and non-small cell lung carcinoma.